AbbVie Exercises its Option to License Agreement for BioArctic's Alpha-Synuclein Antibody Portfolio- Signed in 2016
Shots:
- BioArctic to get $755M as total deal value (with upfront previously paid) and $50M milestone payments in addition to royalties on sales
- In 2016- AbbVie and BioArctic ($80M upfront) entered into a global collaboration to develop & commercialize BioArctic’s Alpha-Synuclein Ab Platform to treat Parkinson Disease
- BAN0805- a leading BioArctic’s Alpha-Synuclein Ab indicated for Parkinson Disease progression- while its IND is under process to onset its first clinical study in 2019
Ref: BioArctic| Image: AbbVie
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com